Código del ensayo TAVT-45 |
Ensayo Phase 3 randomized, open-label study to evaluate the pharmacodynamic effect and safety profile of TAVT-45 compared to Zytiga (reference abiraterone acetate formulation, hereafter referred to as R-AA) in patients with mCSPC and mCRPC. Randomization will be stratified by prostate cancer population (CSPC vs CRPC) and baseline testosterone (<10 vs ? 10 ng/dL). Patients will be treated for 84 days and randomized into one of two groups in a 1:1 ratio |
Estado Abierto a inclusión |
Localización Tumoral Genitourinario |
Tipo de tumor Próstata |
Tipo de ensayo Ensayo de Fase III |
Tipo de tratamiento Otros tratamientos |
Situación clínica Metastásico |
Centro |